LONDON (ShareCast) - (Sharecast News) - Autolus Therapeutics reported progress in clinical trials for one of its cancer treatments and said it has begun dosing patients in another trial.
Syncona, which is listed on the Nasdaq in New York and where FTSE 250-listed Syncona is a 33.8% shareholder, its Phase I/II Amelia clinical trial of AUTO3 in patients with relapsed/refractory pediatric acute lymphoblastic leukemia had so far shown a "manageable" safety profile, "with the potential to overcome target-negative relapse", which has proved a limitation of current treatments.

Early results of the ongoing Phase 1/2 Alexander trial of AUTO3 in patients with relapsed/refractory diffuse large B cell lymphoma, also indicate a manageable safety profile.



Meanwhile, a trial of its AUTO4 developmental therapy for the treatment of relapsed or refractory TRBC1-positive peripheral T cell lymphoma has just begun dosing patients.

Furthermore, Autolus presented data over the weekend on the preclinical sister program, AUTO5, targeting TRBC2-positive lymphoma. Autolus' T cell program comprises a companion diagnostic to determine whether the PTCL is TRBC1- or TRBC2-positive and two novel CAR T cell product candidates AUTO4 and AUTO5. The company suggested that employing a structural biology approach and molecular modelling techniques, a binder was generated that could bind TRBC2 without binding to TRBC1, which could selectively eliminated TRBC2-positive cells.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE